Literature DB >> 22692795

The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis.

Tamara Pringsheim1, Katie Wiltshire, Lundy Day, Jonathan Dykeman, Thomas Steeves, Nathalie Jette.   

Abstract

Huntington's disease (HD) is a rare, neurodegenerative disorder characterized by chorea, behavioral manifestations, and dementia. The aim of this study was to estimate the incidence and prevalence of HD through a systematic review of the literature. Medline and Embase databases were searched using terms specific to HD as well as studies of incidence, prevalence, and epidemiology. All studies reporting the incidence and/or prevalence of HD were included. Twenty original research articles were included. Eight studies examined incidence, and 17 studies examined prevalence. Meta-analysis of data from four incidence studies revealed an incidence of 0.38 per 100,000 per year (95% confidence interval [CI]: 0.16, 0.94). Lower incidence was reported in the Asian studies (n = 2), compared to the studies performed in Europe, North America, and Australia (n = 6). The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61). Metaregression revealed a significantly lower prevalence of HD in Asia, compared to European, North American, and Australian populations. HD is a devastating neurodegenerative disorder with a higher prevalence in Europe, North America, and Australia than in Asia. The difference in prevalence of this genetic disorder can be largely explained by huntingtin gene haplotypes.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22692795     DOI: 10.1002/mds.25075

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  146 in total

Review 1.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

2.  Adult neurogenesis and neurodegenerative diseases: A systems biology perspective.

Authors:  Emrin Horgusluoglu; Kelly Nudelman; Kwangsik Nho; Andrew J Saykin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-02-16       Impact factor: 3.568

Review 3.  Adult neurogenesis in neurodegenerative diseases.

Authors:  Beate Winner; Jürgen Winkler
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 4.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

5.  Regional differences in dopamine release in the R6/2 mouse caudate putamen.

Authors:  Sam V Kaplan; Ryan A Limbocker; Beth Levant; Michael A Johnson
Journal:  Electroanalysis       Date:  2018-03-30       Impact factor: 3.223

6.  Understanding the need for assistance with survey completion in people with Huntington disease.

Authors:  Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi
Journal:  Qual Life Res       Date:  2017-12-06       Impact factor: 4.147

7.  HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Authors:  N E Carlozzi; S G Schilling; J-S Lai; J S Paulsen; E A Hahn; J S Perlmutter; C A Ross; N R Downing; A L Kratz; M K McCormack; M A Nance; K A Quaid; J C Stout; R C Gershon; R E Ready; J A Miner; S K Barton; S L Perlman; S M Rao; S Frank; I Shoulson; H Marin; M D Geschwind; P Dayalu; S M Goodnight; D Cella
Journal:  Qual Life Res       Date:  2016-08-13       Impact factor: 4.147

8.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

9.  Clinical and genetic data of Huntington disease in Moroccan patients.

Authors:  Ahmed Bouhouche; Wafaa Regragui; Hind Lamghari; Khadija Khaldi; Nazha Birouk; Safaa Lytim; Soufiane Bellamine; Yamna Kriouile; Naima Bouslam; El Hachmia Ait Ben Haddou; Mustapha Alaoui Faris; Ali Benomar; Mohamed Yahyaoui
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.